ALYSSA ARREDONDO: Open Payments
NPI 1538370036 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$659 in 30 payments from 10 companies in 2025. Trend: 2023 $707 · 2024 $596 · 2025 $659
Food & beverage: $659
| Company | Payments | Amount |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. | 11 | $168 |
| Optinose US, Inc. | 2 | $162 |
| GlaxoSmithKline, LLC. | 4 | $85 |
| GENZYME CORPORATION | 4 | $65 |
| SANOFI-AVENTIS U.S. LLC | 3 | $51 |
| Organon LLC | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
| Genentech USA, Inc. | 1 | $26 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
| ALK-Abello, Inc | 1 | $17 |
Products named: NEFFY, Xhance, DUPIXENT, NUCALA, TRELEGY ELLIPTA, Xolair, Rhapsido, Grastek.
Industry payments across TX — which companies pay providers there.
